Anesthetic Agent Sales Market Segmentation Application, Technology & Research Report to 2022

Anesthetic Agent Sales Market report presents an all-inclusive study of the market by analysing the key development trends, driving forces, restraints, opportunities, and future potential in details.

The report then analyses company profiles and the growth strategies of the major Anesthetic Agent Sales Market leaders. A detailed study of product picture and specifications, revenue, cost, price, gross, capacity and production, company profiles, and contact information is carried out in the analysis of Anesthetic Agent Sales industry key manufacturer’s section.

Get a Sample of Anesthetic Agent Sales Market research report from- http://www.absolutereports.com/enquiry/request-sample/10600053

Both established and new players in the Anesthetic Agent Sales Market can use this report for complete understanding of the market.

A thorough analysis of price, market share, and gross margin on the basis of product type, price levels, and applications is done in the price and gross margin analysis section of the Anesthetic Agent Sales Market research report.

Detailed TOC and Charts & Tables of Anesthetic Agent Sales Market Research Report available at- https://www.absolutereports.com/global-anesthetic-agent-sales-market-report-2017-10600053

Several important topics included in the Anesthetic Agent Sales Market research report are as follows:

  • Production Analysis of Anesthetic Agent Sales Market
  • Industry key players’ analysis of Anesthetic Agent Sales Market
  • Price and Gross Margin Analysis of Anesthetic Agent Sales Market
  • Development Trend of Anesthetic Agent Sales Market
  • Feasibility analysis of new project investments for Anesthetic Agent Sales Market

 

The production analysis section covers a thorough study of regional production on the basis of region, type, and application. Along with this several other aspects such as cost, revenue, price, import, export, capacity, and production are also analysed in the production analysis of the Anesthetic Agent Sales Market.

  • United States
  • China
  • Europe
  • Japan
  • India
  • Southeast Asia

Topics such as sales and sales revenue overview, production market share by product type, capacity and production overview, import, export, and consumption are covered under the development trend section of the Anesthetic Agent Sales Market report.

Lastly, the feasibility analysis of new project investment is done in the report, which consist of a detailed SWOT analysis of the Anesthetic Agent Sales Market.

No. of Report Pages: 126

Price (Single User Licence): $4000

Purchase the Anesthetic Agent Sales Market Report at: http://www.absolutereports.com/purchase/10600053

Delta builds on position as leading global carrier in Boston

Delta customers in Greater Boston will have more flights and new destinations this summer as the airline adds new nonstop service to Austin, Texas; Kansas City, Mo.*; Jacksonville, Fla.*; Buffalo, N.Y.*; and Norfolk, Va.*; – a new nonstop destination for Bostonians – as well as a second daily flight to Nashville, Tenn.*, from Boston Logan International Airport beginning Sept. 10.

“Delta is committed to being Boston’s global carrier of choice with service that meets the needs of both business and leisure travelers,” said Bob Cortelyou, Delta’s Senior Vice President – Network Planning. “Our growing network is built to support the diverse travel demands of our customers with unparalleled overall operational performance, and innovative products and services.

On Dec. 21, Delta will expand weekend West Palm Beach, Fla., and Fort Myers, Fla., flights to daily, as well as increase weekend Ft. Lauderdale, Fla., flights to twice daily. Delta will also continue to support strong holiday travel demand with nonstop flights to popular Caribbean destinations including Montego Bay, Jamaica; Punta Cana, Dominican Republic; St. Thomas, U.S. Virgin Islands; and Nassau, Bahamas; beginning Dec. 21.

“Delta’s new flights and growing presence at Logan Airport are welcome news to the Commonwealth as we strive to strengthen our economic environment and create more connections across the country and globe,” said Massachusetts Gov. Charlie Baker. “Not only will these new flights increase options for travelers coming to and from Boston, but the planned increase to more than 100 daily flights out of Logan is a clear indication that connecting to the Commonwealth continues to be in demand.”

Delta’s previously announced nonstop service to Dublin, beginning May 25, and transcontinental service to San Francisco, beginning June 8, combined with the other eight routes, complements existing trans-Atlantic service to Amsterdam, London-Heathrow and Paris-Charles de Gaulle.   

When paired with additional joint venture partner and SkyTeam flights to Paris-Charles de Gaulle, London-Heathrow, Manchester, Rome and Mexico City, the combined group of Delta, Air France-KLM, Virgin Atlantic, Alitalia and Aeromexico offers customers seamless, one-connection access to 174 destinations in Europe and Latin America.

Delta offers more capacity to Europe from Boston than any other U.S. carrier, and is the only U.S. global carrier to offer full flat-bed seats with direct aisle access in Delta One. In addition, Delta One customers enjoy Westin Heavenly In-Flight Bedding featuring a full-size pillow and quilted comforter, chef-designed cuisine, a wine program curated by Master Sommelier Andrea Robinson, a TUMI amenity kit featuring Kiehl’s Since 1851 skincare products and an Alessi-designed collection of serviceware. Customers flying in Delta Comfort+ will benefit from up to four additional inches of legroom and 50 percent more recline than Main Cabin seats, as well as priority boarding, and every customer will enjoy Delta Studio, which includes hundreds of complimentary movies, TV shows, songs and games, and the ability to connect with Wi-Fi on every flight.

Delta offers the most first class seats of any airline from Boston, and by this fall will operate more than 100 peak day departures to 32 destinations. The airline’s rapid growth includes 12 new destinations since November 2016.

“Logan International Airport has seen tremendous growth over the past decade and we are pleased that Delta is continuing that streak with this exciting announcement,” said Massport CEO Thomas P. Glynn. “Over 36 million people traveled through Logan last year, many of them on Delta, and with this new milestone, we are looking forward to serving even more.”

Delta is the No. 1 carrier between Boston and New York connecting business travelers with the Delta Shuttle, operated by Delta and its connection partner Shuttle America, with hourly service 16 times daily between Logan Airport and New York City’s LaGuardia Airport as well as offering eight daily flights to JFK. Delta Sky Club operates two locations in Terminal A providing customers with several healthy and fresh food choices and a number of complimentary drink options including local Samuel Adams craft beer and Starbucks coffee. THE BAR at Delta Sky Club offers wines and premium spirits. SkyMiles members can use miles for premium drinks with a swipe their boarding pass.

Delta offers Delta Studio, the airline’s industry-leading suite of onboard entertainment, free for all customers on two-class aircraft. Delta operates the world’s largest Wi-Fi-equipped fleet, with more than 1,000 connected Delta aircraft, including the airline’s entire fleet of 680 domestic mainline aircraft, Delta Connection two-class regional jets and all of its widebody international fleet.

Aneroid Sphygmomanometers Sales Market Analysis, Size, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts 2017 To 2022

Aneroid Sphygmomanometers Sales Market report presents an all-inclusive study of the market by analysing the key development trends, driving forces, restraints, opportunities, and future potential in details.

The report then analyses company profiles and the growth strategies of the major Aneroid Sphygmomanometers Sales Market leaders. A detailed study of product picture and specifications, revenue, cost, price, gross, capacity and production, company profiles, and contact information is carried out in the analysis of Aneroid Sphygmomanometers Sales industry key manufacturer’s section.

Major Key Players are also Analyzed in the Aneroid Sphygmomanometers Sales Market Report such as:

  • A&D Medical
  • Ge
  • Omron
  • Philips
  • Suntech Medical
  • Welch Allyn
  • American Diagnostic
  • Beurer
  • Bosch + Sohn
  • Briggs Healthcare
  • Choicemmed
  • Citizen

Get a Sample of Aneroid Sphygmomanometers Sales Market research report from- http://www.absolutereports.com/enquiry/request-sample/10600977

Both established and new players in the Aneroid Sphygmomanometers Sales Market can use this report for complete understanding of the market.

A thorough analysis of price, market share, and gross margin on the basis of product type, price levels, and applications is done in the price and gross margin analysis section of the Aneroid Sphygmomanometers Sales Market research report.

Detailed TOC and Charts & Tables of Aneroid Sphygmomanometers Sales Market Research Report available at- https://www.absolutereports.com/global-aneroid-sphygmomanometers-sales-market-report-2017-10600977

Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into

  • Wrist
  • Arm Type

Split by applications, this report focuses on sales, market share and growth rate of Aneroid Sphygmomanometers in each application, can be divided into

  • Hospital
  • Clinic
  • Family

Several important topics included in the Aneroid Sphygmomanometers Sales Market research report are as follows:

  • Production Analysis of Aneroid Sphygmomanometers Sales Market
  • Industry key players’ analysis of Aneroid Sphygmomanometers Sales Market
  • Price and Gross Margin Analysis of Aneroid Sphygmomanometers Sales Market
  • Development Trend of Aneroid Sphygmomanometers Sales Market
  • Feasibility analysis of new project investments for Aneroid Sphygmomanometers Sales Market

The production analysis section covers a thorough study of regional production on the basis of region, type, and application. Along with this several other aspects such as cost, revenue, price, import, export, capacity, and production are also analysed in the production analysis of the Aneroid Sphygmomanometers Sales Market.

  • United States
  • China
  • Europe
  • Japan
  • India
  • Southeast Asia

Topics such as sales and sales revenue overview, production market share by product type, capacity and production overview, import, export, and consumption are covered under the development trend section of the Aneroid Sphygmomanometers Sales Market report.

Lastly, the feasibility analysis of new project investment is done in the report, which consist of a detailed SWOT analysis of the Aneroid Sphygmomanometers Sales Market.

No. of Report Pages: 124

Price (Single User Licence): $4000

Purchase the Aneroid Sphygmomanometers Sales Market Report at: http://www.absolutereports.com/purchase/10600977

Clear disregard for the safety of workers and others

26 April 2017

Clear disregard for the safety of workers and others

Sub-optimal demolition work of three residential buildings placed workers and neighbours at significant risk of asbestos exposure and landed the home owner with a large clean-up bill.

The dangers of asbestos have long been recognised which is why the extensive failings of P&M Demolition Specialists Ltd and its sole Director, Jade Ngaha, are so disturbing.

WorkSafe’s investigation found that P&M Demolition Specialists and Mr Ngaha had been told of asbestos containing material on site. Despite this, there was neither a risk assessment nor a comprehensive survey to establish the location, condition and quantity of asbestos containing material. Instead the demolition work proceeded with no safety controls in place, exposing workers and neighbours to asbestos fibres and asbestos containing dust. Asbestos dust was found well beyond the boundary of the worksite.

“It’s beyond belief that Mr Ngaha did not follow recognised industry practice which includes testing for the presence of asbestos given he had been told that it was present. Nor did he ensure his employees had the right skills or equipment for the task,” said Keith Stewart, WorkSafe Chief Inspector.

“Asbestos is very dangerous and the importance of having specialist knowledge and help to manage its removal is critical to reduce risk. Safety is paramount when it comes to asbestos and that is why the regulations are so detailed,” added Mr Stewart.

Asbestos is the single biggest cause of deaths from work-related disease. On average about 170 people die every year from asbestos-related diseases. Breathing in airborne asbestos fibres is a serious risk to health – once the fibres are breathed in, they lodge in the lungs and may cause asbestosis, lung cancer or mesothelioma.

[Ends]

Notes:

P&M Demolition Specialists pleaded guilty to three charges under Health and Safety in Employment Act 1992 for failing to take all practicable steps to protect its workers and others.

Jade Ngaha, sole director of P&M Demolition Specialists, also plead guilty to three charges under the Health and Safety in Employment Act 1992 for his part in P&M Demolition Specialists’ failings.

• P&M Demolition Specialists were charged under S6, S16, S18 and S50 of the Health and Safety in Employment Act 1992. The charges carry a maximum fine of $250,000

• Jade Ngaha was charged under S6, S16, S18, S50 and S56 of the Health and Safety in Employment Act 1992. The charges carry a maximum fine of $250,000

• Due to the financial position of the company and Mr Ngaha, the North Shore District Court did not impose a fine.

• However, reparations of $36,000 were ordered in addition to the $13,000 already paid towards the clean-up costs.

© Scoop Media

Textainer Selects RAM’s Fixed Asset Software to Meet Corporate Governance Requirements

ORPINGTON, ENGLAND, April 26, 2017 /PRNewswire/ --

Textainer, a leader in the intermodal container leasing industry, has selected software from Real Asset Management (RAM) to manage its fixed assets in accordance with US GAAP and IFRS regulations.

     (Logo: http://photos.prnewswire.com/prnh/20160201/327800LOGO )

Textainer decided to replace an older system with RAM's software to accommodate growth and to comply with processes that had changed over time at the company. Gregory Coan, Chief Information Officer at Textainer comments, "Our previous solution was written in-house 13 years ago. While it has served us well, our fleet size has grown dramatically and the dynamics of our business have evolved. This led us to the purchase of a new, specialist tool that can be tailored to our requirements and that delivers crucial functionality when it comes to fixed asset management."

The solution provides a platform to manage the fundamentals of asset accounting whilst also helping towards compliance with all financial directives. It enables organisations to meet IFRS and US GAAP regulations, including the upcoming IFRS 16 lease accounting rules that were agreed between the IASB and FASB and that will become effective in 2019.

"Textainer was familiar with RAM as it previously provided software to Amficon, a company we acquired in 2009," Coan continued. "Our work with RAM during the migration of that fleet into our systems contributed to the confidence we had in engaging them for this requirement."

Headquartered in Bermuda, Textainer operates via a network of 14 offices and 400 depots worldwide. With a fleet of over 3.2 million TEU, it supplies more than 400 customers including some of the world's largest shipping lines.

Real Asset Management (RAM) is a leading provider of fixed asset management and intermodal software & services. Over the last 30 years, its products have been implemented by more than 3,000 organisations in over 70 countries.

The company has developed a powerful range of software modules around a central data repository that enables organisations of any size to manage every aspect of the asset lifecycle. Its Series4000 solution offers fixed asset accounting, capital project control, lease accounting, asset budgeting, asset tracking (utilising barcode/RFID/NFC technology) and computerised maintenance management.

In the intermodal transport sector, RAM Intermodal Software offers specialist software, providing sales, marketing, operations and finance teams with a complete set of tools for managing the processes involved in international tank operating and container leasing.

For further information, please contact:
Nicola Byers
Real Asset Management 
Tel: +44-(0)-1689-892153
Email: nbyers@realassetmgt.com

Shire Granted EU Conditional Marketing Authorisation for Natpar[(R)   ] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism

ZUG, Switzerland, April 26, 2017 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the first recombinant human protein with the full length 84-amino acid sequence of endogenous parathyroid hormone (PTH). Natpar will be the first and only approved hormone therapy indicated as adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.[1] Hypoparathyroidism is a rare endocrine disease resulting from an inappropriately low circulating PTH concentration.[2]

''As the first and only licensed recombinant parathyroid hormone treatment in Europe for chronic hypoparathyroidism, Natpar represents a historical and timely innovation for patients who cannot be adequately controlled on calcium and vitamin D alone," said Philip J. Vickers, Ph.D., Global Head of Research and Development at Shire. "The approval of Natpar offers an important advance in the management of this rare endocrine disorder for patients in Europe."

The Conditional Marketing Authorisation is based on the outcomes from the Phase III efficacy and safety of rhPTH(1-84) clinical trial (REPLACE) in patients aged 19-74 years with chronic hypoparathyroidism.[1] The trial showed that Natpar maintained serum calcium while reducing oral calcium and active vitamin D supplemental doses.[1]

"Chronic hypoparathyroidism can carry a significant disease burden, and some patients are not well-controlled, showing fluctuations in their serum calcium levels,[3]" said Professor Maria Louisa Brandi, Department of Internal Medicine, University of Florence, Italy. "Clinical studies have shown Natpar maintains serum calcium while reducing the need for calcium and vitamin D for patients with chronic hypoparathyroidism.[1]"

With this approval, Shire is now authorized to market Natpar in the 28 Member States of the European Union (EU), as well as in Iceland, Liechtenstein and Norway. Natpar falls under the scope of European Commission Regulation as eligible for Conditional Marketing Authorisation because it is designated as an orphan medicinal product and fulfils an unmet medical need.

About hypoparathyroidism 

Hypoparathyroidism is a rare disease that occurs when inadequate levels of PTH are secreted by the parathyroid glands, resulting in a mineral imbalance in the body expressed by a low concentration of calcium (hypocalcemia) and a high concentration of phosphate (hyperphosphatemia) in the blood.

Guidelines from the European Society of Endocrinology (ESE) state that a diagnosis of chronic hypoparathyroidism should be considered in a patient with hypocalcemia and an inappropriately low PTH concentration. Guidelines recommend that treatment should aim to restore mineral homeostasis and prevent symptoms of hypocalcemia while optimizing overall well-being. Typical symptoms of hypocalcemia include muscle spasms and cramping.

To date, management of chronic hypoparathyroidism has focused on maintaining serum calcium with oral calcium and active vitamin D supplements; however, some patients are not adequately controlled and still have variations in their serum calcium levels.[3]-[6]

About Natpar 

Natpar is a recombinant human PTH and will be available as a 25, 50, 75 and 100 micrograms once-daily injection as adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.

Natpar is approved in the United States under the trade name Natpara® (parathyroid hormone).

About the REPLACE study 

In the double-blind, placebo-controlled, randomized Phase III study 124 patients with hypoparathyroidism were randomized in a ratio of 2:1 to either 50 micrograms once daily of rhPTH(1-84) or placebo for 24 weeks. The primary endpoint was a 50 percent or greater reduction from baseline in their daily dose of oral calcium and active vitamin D while maintaining a stable albumin corrected serum calcium concentration greater than or equal to baseline concentration (baseline was 2.1 mmol/L for the rhPTH[1-84] group and 2.2 mmol/L for the placebo group) and less or equal to the upper limit of normal (normal range 2.1-2.6 mmol/L). At the end of the treatment period, 54.8 percent of the patients on rhPTH(1-84) achieved the primary endpoint compared with 2.5 percent of patients in the placebo group (p<0.0001).[1] There were no differences in the proportion of patients maintaining a stable albumin corrected serum calcium concentration at the end of treatment between subjects randomized to rhPTH (1-84) and placebo.[7]

Natpar Safety Information for Europe 

Please consult the Natpar Summary Product Characteristics (SmPC) before prescribing.

Natpar treatment should be supervised by a physician or other qualified healthcare professional experienced in the management of patients with hypoparathyroidism.

Contraindications
Natpar is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, who are receiving or who have previously received radiation therapy to the skeleton, with skeletal malignancies or bone metastases, who are at increased baseline risk for osteosarcoma, with unexplained elevations of bone-specific alkaline phosphatase, with pseudohypoparathyroidism.  

Warnings and Precautions 

Monitoring of patients during treatment pre-dose and in some cases post-dose serum calcium levels must be monitored during treatment with Natpar.

Hypercalcemia this was reported in clinical trials with Natpar. Hypercalcemia commonly occurred during the titration period, during which doses of oral calcium, active vitamin D, and Natpar were being adjusted. Hypercalcemia may be minimized by following the recommended dosing, the monitoring information and asking patients about any symptoms of hypercalcemia. If severe hypercalcemia develops, hydration and temporarily stopping Natpar, calcium and active vitamin D should be considered until serum calcium returns to the normal range. Then consider resuming Natpar, calcium and active vitamin D at lower doses.

Hypocalcemia a common clinical manifestation of hypoparathyroidism, was reported in clinical trials with Natpar. Most of the hypocalcemic events occurring in the clinical trials were mild to moderate severity. The risk for serious hypocalcemia was greatest after the withdrawal of Natpar. Temporary or permanent discontinuation of Natpar must be accompanied by monitoring of serum calcium levels and increase of exogenous calcium and/or vitamin D sources as necessary. Hypocalcemia may be minimized by following the recommended dosing, the monitoring information, and asking patients about any symptoms of hypocalcemia.

Concomitant use with cardia glycosides Hypercalcaemia of any cause may predispose to digitalis toxicity, monitor serum calcium and cardiac glycoside levels and patients for signs and symptoms of digitalis toxicity.

Severe renal or hepatic disease Natpar should be used with caution in patients with severe renal or hepatic disease because they have not been evaluated in clinical trials.

Use in young adults Natpar should be used with caution in young adult patients with open epiphyses.

Tachyphylaxis the calcium-raising effect of Natpar may diminish over time in some patients. The response of serum calcium concentration to administration of Natpar should be monitored at intervals to detect this and the diagnosis of tachyphylaxis considered.

Adverse Reactions 

The most commonly observed adverse events with Natpar treatment were hypercalcaemia, hypocalcaemia, headache, diarrhea, vomiting, paraesthesia, hypoesthesia and hypercalciuria.


   
    Very common

    (frequency        Hypercalcemia, hypocalcaemia, headache, hypoesthesia,
    greater than or   paraesthesia, diarrhoea, nausea, vomiting, arthralgia, and
    equal to1/10):    muscle spasms.
    Common            Hypomagnesaemia, tetany, anxiety, insomnia, somnolence,
                      palpitations, hypertension, cough, abdominal pain upper,
                      muscle twitching, musculoskeletal pain, myalgia, neck pain,
                      pain in extremity, hypercalciuria, pollakiuria, asthenia,
    (greater than or  chest pain, fatigue, injection site reactions, thirst,
    equal to1/100 to  anti-PTH antibody positive, blood 25-hydroxycholecalciferol
    <1/10):           decreased, vitamin D decreased.

 

NOTES TO EDITORS 

About Shire 

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

http://www.shire.com

Forward-Looking Statements 

Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:

  • Shire's products may not be a commercial success;
  • increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire's future revenues, financial condition and results of operations;
  • Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers to manufacture other products and to provide goods and services. Some of Shire's products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire's products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
  • the manufacture of Shire's products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • certain of Shire's therapies involve lengthy and complex processes, which may prevent Shire from timely responding to market forces and effectively managing its production capacity;
  • Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
  • the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire's revenues, financial conditions or results of operations;
  • Shire's products and product candidates face substantial competition in the product markets in which it operates, including competition from generics;
  • adverse outcomes in legal matters, tax audits and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the Company's revenues, financial condition or results of operations;
  • inability to successfully compete for highly qualified personnel from other companies and organizations;
  • failure to achieve the strategic objectives, including expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all with respect to Shire's acquisitions, including NPS Pharmaceuticals Inc., Dyax Corp. or Baxalta Incorporated may adversely affect Shire's financial condition and results of operations;
  • Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products;
  • a slowdown of global economic growth, or economic instability of countries in which Shire does business, as well as changes in foreign currency exchange rates and interest rates, that adversely impact the availability and cost of credit and customer purchasing and payment patterns, including the collectability of customer accounts receivable;
  • failure of a marketed product to work effectively or if such a product is the cause of adverse side effects could result in damage to Shire's reputation, the withdrawal of the product and legal action against Shire;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
  • Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which may decrease its business flexibility and increase borrowing costs; and

a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in "ITEM 1A: Risk Factors", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.

All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

References 

  1. Natpar® Summary of Product Characteristics.
  2. Bilezikian JP, et al. J Clin Endocrinol Metab. 2016;101:2313-2324.
  3. Mitchell DM, et al. J Clin Endocrinol Metab. 2012;97:4507-4514.
  4. Bollerslev J, et al. Eur J Endocrinol. 2015;173:G1-G20.
  5. Brandi ML, et al. J Clin Endocrinol Metab. 2016;101:2273-2283.
  6. Hadker N, et al. Endocr Pract. 2014;20:671-679.
  7. Mannstadt M, et al. Lancet Diabetes Endocrinol. 2013;1:275-283.


For further information, please contact:

Investor Relations
Ian Karp
ikarp@shire.com

+1-781-482-9018

Robert Coates
rcoates@shire.com
+44(0)1256-894874

Media
Annabel Cowper
annabel.cowper@shire.com
+41-79-630-8619

Debbi Ford  
debbi.ford@shire.com
+1-617-949-9083


Polyplastics Develops New DURAFIDE (R) PPS Grades with Improved Heat Shock Resistance

- Better Materials for Automotive Components and Others -

TOKYO, April 26, 2017 /PRNewswire/ -- Polyplastics Co., Ltd. has developed new DURAFIDE (R) PPS grades, 6150T73 and 6150T8, which applied advanced technology to improve heat shock resistance of highly filled, high-toughness PPS materials.

(Image: http://prw.kyodonews.jp/prwfile/release/M100475/201704211145/_prw_PI1fl_B49uBz0Y.jpg)

Polyphenylene sulfide (PPS) is a highly heat-resistant resin that is categorized as super engineering plastic. It exhibits outstanding flame retardancy, mechanical property, dimensional stability and chemical resistance. In order to meet market requirements, particularly in the automotive sector, we have been making efforts to develop new highly filled, high-toughness PPS grades with greatly improved heat shock resistance.

Previously, it was not so easy to improve heat shock resistance of a PPS material while keeping other properties in balance. First, conventional grades with improved heat shock resistance generate large quantities of mold deposits, caused by gases originating from the impact modifier. And increased frequency of metal mold maintenance was an issue. Second, the trend toward reduction of product thickness and weight has resulted in an increased requirement for materials with higher flowability. However, increasing flowability and improving toughness to give heat shock resistance normally have conflicting effects and it was difficult to achieve both at the same time.

Polyplastics has now developed the new grades DURAFIDE PPS 6150T73 and 6150T8 that have overcome the abovementioned problems. DURAFIDE PPS 6150T8 exhibits high flowability and improved heat shock resistance, while DURAFIDE PPS 6150T73 benefits from even higher heat shock resistance. Additionally, both grades demonstrate low outgassing (low mold deposit) characteristics. These new materials are expected to boost productivity at customers not only in the automotive sector but in a wide range of fields by helping to increase freedom of product design while also reducing the frequency of metal mold maintenance. Polyplastics is not only a developer of materials technology; it is also actively engaged in the development of molding and processing technologies. In addition to the abovementioned materials technologies, we aim to offer new solutions that combine molding and processing technologies.

For more information, visit https://www.polyplastics.com/en/product/lines/pps_hs/index.vm

DURAFIDE (R) is a registered trademark of Polyplastics Co., Ltd. in Japan and other countries.

SOURCE Polyplastics Co., Ltd.

Epiq Announces Platinum Sponsorship of the Innoxcell Annual Symposium, Hong Kong 2017

EPIQ Systems's picture

Printer-friendly versionPrinter-friendly version

eDiscovery experts to speak at international legal and regulatory compliance conference

 HONG KONG – 26 April, 2017 — Epiq, a leading global provider of integrated technology solutions and services for the legal profession, is pleased to announce its sponsorship of the Innoxcell Annual Symposium, Hong Kong 2017. The event will host more than 400 legal and compliance executives in Hong Kong from 26 – 27 April.

 

Three Epiq experts will speak at the event on 26th April:

09:05 – 09:50 – For a panel discussion on “Anti-Corruption: Global Enforcement Trends and Managing eDiscovery in Investigation”  

  • In this session, Sebastian Ko, regional director, document review services & legal counsel APAC (moderator) and Jay Chong, regional director, forensic services APAC (panelist), will discuss:

    • How eDiscovery technologies can be leveraged to manage complex evidentiary disclosures

    • How to conduct investigations driven by FCPA and local authorities with cost-efficient and defensible practices

 14:10 – 14:55 – For a presentation on “eDiscovery’s Past, Present and Future: How Did We Get Here and Where are We Going”

  • In this session, Adi Elliot, vice president of market planning, will explore emerging business data and industry trends that are impacting eDiscovery.

Click here to register for the event.

About Epiq

Epiq is a leading global provider of integrated technology and services for the legal profession, including electronic discovery, bankruptcy, class action and mass tort administration, federal regulatory actions and data breach responses. Our innovative solutions are designed to streamline the administration of litigation, investigations, financial transactions, regulatory compliance and other legal matters. Epiq’s subject-matter experts bring clarity to complexity, create efficiency through expertise and deliver confidence to our clients around the world. For more information, visit us at www.epiqsystems.com.

Copy this html code to your website/blog to embed this press release.

In-depth Research Report on Global Home Security Systems Market 2016

“Global Home Security Systems Market Research Report 2016”Purchase This Report by calling ResearchnReports.com at +1-888-631-6977.

 

This report includes an in-depth overview of the current state of Home Security Systems market and projects its growth and every other crucial elements across major regional markets. It presents a colossal amount of market data that has been gathered with the help of various number of primary and secondary research techniques. The data of this report has been narrowed down using several industry based analytical methodologies.

 

For sample PDF pages click here at:

https://www.researchnreports.com/request_sample.php?id=41623

 

A detailed overview of key market drivers, trends, restraints and analyzes the way they affect the Home Security Systems market in a positive as well as the negative aspect. The regions which are covered in this report are North America, Europe, Asia Pacific, Middle East & Africa and Latin America. Considering the given forecast period and precisely studying each and every yearly data, a report is been drafted to ensure the data is as expected by client.

The report also evaluates the regulatory scenarios which affect various decisions in the Home Security Systems market. It also provides a detailed data about the plans, rule, regulations and policies with respect to this market. After compiling all data, this report forms an excellent report repository which can help gain maximum knowledge with respect to Home Security Systems market. With help of this reports, clients can understand the market strategies and make right decisions.

 

Get 30% Discount on This Report at: https://www.researchnreports.com/ask_for_discount.php?id=41623

 

This report defines the specifications, applications, classifications of Home Security Systems market and explains the industrial chain structure in detail. Recent policies and developments are researched in depth to help enhance this report. A detailed cost structure is examined and prices are coated by labors, raw material supplier and others. An insight about demand supply chain is also mentioned in detail.

A competitive landscape of the market allows the client to get a better overview of future challenges to be faced. Detailed business profiles are discussed with respect to Home Security Systems market allowing the reader to understand the strength and weakness of competitors.

 

Table of Contents:

Global Home Security Systems Market Research Report 2016

1 Home Security Systems Market Overview

1.1 Product Overview and Scope of Home Security Systems

1.2 Home Security Systems Segment by Type

1.2.1 Global Production Market Share of Home Security Systems by Type in 2015

1.2.2 Type I

1.2.3 Type II

1.2.4 Type III

1.3 Home Security Systems Segment by Application

1.3.1 Home Security Systems Consumption Market Share by Application in 2015

1.3.2 Application 1

1.3.3 Application 2

1.3.4 Application 3

1.4 Home Security Systems Market by Region

1.4.1 North America Status and Prospect (2011-2021)

1.4.2 Europe Status and Prospect (2011-2021)

1.4.3 China Status and Prospect (2011-2021)

1.4.4 Japan Status and Prospect (2011-2021)

1.4.5 Korea Status and Prospect (2011-2021)

1.4.6 Taiwan Status and Prospect (2011-2021)

1.5 Global Market Size (Value) of Home Security Systems (2011-2021)

2 Global Home Security Systems Market Competition by Manufacturers

2.1 Global Home Security Systems Production and Share by Manufacturers (2015 and 2016)

2.2 Global Home Security Systems Revenue and Share by Manufacturers (2015 and 2016)

2.3 Global Home Security Systems Average Price by Manufacturers (2015 and 2016)

2.4 Manufacturers Home Security Systems Manufacturing Base Distribution, Sales Area and Product Type

2.5 Home Security Systems Market Competitive Situation and Trends

2.5.1 Home Security Systems Market Concentration Rate

2.5.2 Home Security Systems Market Share of Top 3 and Top 5 Manufacturers

2.5.3 Mergers & Acquisitions, Expansion

3 Global Home Security Systems Production, Revenue (Value) by Region (2011-2016)

3.1 Global Home Security Systems Production by Region (2011-2016)

3.2 Global Home Security Systems Production Market Share by Region (2011-2016)

3.3 Global Home Security Systems Revenue (Value) and Market Share by Region (2011-2016)

3.4 Global Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

3.5 North America Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

3.6 Europe Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

3.7 China Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

3.8 Japan Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

3.9 Korea Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

3.10 Taiwan Home Security Systems Production, Revenue, Price and Gross Margin (2011-2016)

4 Global Home Security Systems Supply (Production), Consumption, Export, Import by Regions (2011-2016)

4.1 Global Home Security Systems Consumption by Regions (2011-2016)

4.2 North America Home Security Systems Production, Consumption, Export, Import by Regions (2011-2016)

4.3 Europe Home Security Systems Production, Consumption, Export, Import by Regions (2011-2016)

4.4 China Home Security Systems Production, Consumption, Export, Import by Regions (2011-2016)

4.5 Japan Home Security Systems Production, Consumption, Export, Import by Regions (2011-2016)

4.6 Korea Home Security Systems Production, Consumption, Export, Import by Regions (2011-2016)

4.7 Taiwan Home Security Systems Production, Consumption, Export, Import by Regions (2011-2016)

5 Global Home Security Systems Production, Revenue (Value), Price Trend by Type

5.1 Global Home Security Systems Production and Market Share by Type (2011-2016)

5.2 Global Home Security Systems Revenue and Market Share by Type (2011-2016)

5.3 Global Home Security Systems Price by Type (2011-2016)

5.4 Global Home Security Systems Production Growth by Type (2011-2016)

6 Global Home Security Systems Market Analysis by Application

6.1 Global Home Security Systems Consumption and Market Share by Application (2011-2016)

6.2 Global Home Security Systems Consumption Growth Rate by Application (2011-2016)

6.3 Market Drivers and Opportunities

6.3.1 Potential Applications

6.3.2 Emerging Markets/Countries

7 Global Home Security Systems Manufacturers Profiles/Analysis

7.1 LiveWatch

7.2 MONI

7.3 Frontpoint

7.4 Protection 1

7.5 Protect America

7.6 ADT

8 Home Security Systems Manufacturing Cost Analysis

8.1 Home Security Systems Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Price Trend of Key Raw Materials

8.1.3 Key Suppliers of Raw Materials

8.1.4 Market Concentration Rate of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.2.1 Raw Materials

8.2.2 Labor Cost

8.2.3 Manufacturing Expenses

8.3 Manufacturing Process Analysis of Home Security Systems

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

9.1 Home Security Systems Industrial Chain Analysis

9.2 Upstream Raw Materials Sourcing

9.3 Raw Materials Sources of Home Security Systems Major Manufacturers in 2015

9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

11 Market Effect Factors Analysis

11.1 Technology Progress/Risk

11.1.1 Substitutes Threat

11.1.2 Technology Progress in Related Industry

11.2 Consumer Needs/Customer Preference Change

11.3 Economic/Political Environmental Change

12 Global Home Security Systems Market Forecast (2016-2021)

12.1 Global Home Security Systems Production, Revenue Forecast (2016-2021)

12.2 Global Home Security Systems Production, Consumption Forecast by Regions (2016-2021)

12.3 Global Home Security Systems Production Forecast by Type (2016-2021)

12.4 Global Home Security Systems Consumption Forecast by Application (2016-2021)

12.5 Home Security Systems Price Forecast (2016-2021)

13 Research Findings and Conclusion

 

Complete report available at : https://www.researchnreports.com/semiconductor-electronics/Global-Home-Security-Systems-Market-Research-Report-2016-41623

 

About Research n Reports:

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut throat global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently we keep evolving as an all-rounder provider of viable information under one roof.

 

Contact us:

Mr. Sunny Denis

Contact No. +1-888-631-6977

sales@researchnreports.com

(ResearchnReports)

Prochloraz Market 2022: Competition by Top Manufacturers, With Production, Revenue (Value) and Market Share

Prochloraz Market size is anticipated to see significant growth prospects from 2017 to 2022. The objective of Prochloraz market report is to provide a detailed analysis of the Prochloraz industry and its impact based on applications and on different geographical regions; strategically analyse the growth trends, future prospects: R&D spending and trail investments.

Prochloraz Market development trends and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

To begin with, the report elaborates the Prochloraz Market overview. Various definitions and classification of the industry, applications of the industry and chain structure are given. Present day status of the Prochloraz Industry in key regions is stated and industry policies and news are analysed.

For Any Query, Contact Our Expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10570965  

Prochloraz Market Table of Contents:

Chapter 1 Overview of Prochloraz Market
1.1 Brief Overview of Prochloraz
1.2 Development of Prochloraz Market
1.3 Status of Prochloraz Market

Chapter 2 Manufacturing Technology of Prochloraz Market
2.1 Development of Prochloraz Manufacturing Technology
2.2 Analysis of Prochloraz Manufacturing Technology
2.3 Trends of Prochloraz Manufacturing Technology

Chapter 3 Analysis of Global Prochloraz Market Key Manufacturers
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 2012-2017 Production Information
3.1.4 Contact Information

Chapter 4 2012-2017 Global and Chinese Prochloraz Market
4.1 2012-2017 Global Capacity, Production and Production Value of Prochloraz Market
4.2 2012-2017 Global Cost and Profit of Prochloraz Market
4.3 Market Comparison of Global and Chinese Prochloraz Market
4.4 2012-2017 Global and Chinese Supply and Consumption of Prochloraz
4.5 2012-2017 Chinese Import and Export of Prochloraz

Chapter 5 Market Status of Prochloraz Industry
5.1 Market Competition of Prochloraz Industry by Company
5.2 Market Competition of Prochloraz Industry by Country (USA, EU, Japan, Chinese etc.)
5.3 Market Analysis of Prochloraz Consumption by Application/Type

Chapter 6 2017-2022 Market Forecast of Global and Chinese Prochloraz Market
6.1 2017-2022 Global and Chinese Capacity, Production, and Production Value of Prochloraz market
6.2 2017-2022 Prochloraz market Cost and Profit Estimation
6.3 2017-2022 Global and Chinese Prochloraz Market Share
6.4 2017-2022 Global and Chinese Supply and Consumption of Prochloraz
6.5 2017-2022 Chinese Import and Export of Prochloraz

Chapter 7 Analysis of Prochloraz Industry Chain
7.1 Industry Chain Structure
7.2 Upstream Raw Materials
7.3 Downstream Industry

Chapter 8 Global and Chinese Economic Impact on Prochloraz Market
8.1 Global and Chinese Macroeconomic Environment Analysis
8.1.1 Global Macroeconomic Analysis
8.1.2 Chinese Macroeconomic Analysis
8.2 Global and Chinese Macroeconomic Environment Development Trend
8.2.1 Global Macroeconomic Outlook
8.2.2 Chinese Macroeconomic Outlook
8.3 Effects to Prochloraz Market

Chapter 9 Market Dynamics of Prochloraz Industry
9.1 Prochloraz Industry News
9.2 Prochloraz Industry Development Challenges
9.3 Prochloraz Industry Development Opportunities

Chapter 10 Proposals for New Project
10.1 Prochloraz Market Entry Strategies
10.2 Countermeasures of Economic Impact
10.3 Marketing Channels
10.4 Feasibility Studies of New Project Investment

Ask for Sample @ http://www.absolutereports.com/enquiry/request-sample/10570965  

The report provides key statistics on the market status of the Prochloraz manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Through the statistical analysis, the report portrays the Global and Chinese Complete market of Prochloraz Industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The entire Industry is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2017-2022 market development trends of Prochloraz Industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. After the basic information, the Prochloraz Market report sheds light on the production. Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Prochloraz industry covering all important parameters.

No. of Pages: 150

Price of Report: $ 3000 (Single User Licence)

Get The Report @ http://www.absolutereports.com/purchase/10570965